Concerta, the extended-release brand of methylphenidate hydrochloride, continues to be one of the most prescribed and recognised treatments for attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults in 2026. The unique OROS (osmotic-controlled release oral delivery system) technology releases the drug in a carefully controlled manner: an immediate outer layer provides quick onset […]